Article Text

Download PDFPDF
Randomised controlled trial
An interferon-free, all-oral regimen is effective in treatment of genotype 1 chronic HCV infection
  1. Andrew W Tai
  1. Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
  1. Correspondence to: Dr Andrew W Tai, Department of Internal Medicine, University of Michigan, 6520 MSRB I SPC 5682 1150 W Medical Center Drive, Ann Arbor, MI 48109, USA; andrewwt{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Commentary on: OpenUrlCrossRefPubMedWeb of Science


The current standard-of-care therapy for patients with chronic genotype 1 hepatitis C virus (HCV) infection is a combination of peginterferon, ribavirin and a direct-acting antiviral (DAA) NS3/4A protease inhibitor (telaprevir or boceprevir).1 While this regimen is associated with sustained virological response (SVR) rates of approximately 67–75% among treatment-naïve patients, they are substantially lower in ‘difficult-to-treat’ populations including black patients, those with cirrhosis, and treatment-experienced patients. Furthermore, these medications, particularly peginterferon, are associated with substantial side effects that can limit treatment or preclude therapy initiation. The development of additional DAA classes that target the NS5B RNA polymerase and the NS5A protein opens the door to highly effective and potentially better tolerated interferon-free regimens.


Zeuzem and colleagues conducted a multicentre, randomised, open-label, phase …

View Full Text


  • Competing interests None.